Document |
Document Title |
WO/1999/043659A1 |
A process for producing a pyridone derivative represented by general formula (4), characterized by reacting a compound represented by general formula (1) with a hypochlorite or hypobromite or with lead tetraacetate to give a compound rep...
|
WO/1999/043663A1 |
NHE-1 inhibitors, methods of using such NHE-1 inhibitors and pharmaceutical compositions containing such NHE-1 inhibitors. The NHE-1 inhibitors are useful for the reduction of tissue damage resulting from tissue ischemia.
|
WO/1999/042452A1 |
Phthalazine derivatives represented by general formula (I) or pharmacologically acceptable salts thereof or hydrates of the same usable as remedies for erectile dysfunction, wherein R¿1? and R¿2? are the same or different and each repr...
|
WO/1999/042449A1 |
Nitrogen compounds represented by formula (XXIa) or (XXIb); an epoxy resin hardening accelerator and a resin composition each containing any of the compounds; and an electronic part device containing an element encapsulated with the comp...
|
WO/1999/042461A1 |
Quinoxaline compounds are described as well as method for the preparation and pharmaceutical compositions of same, which are useful as interleukin-8 (IL-8) receptor antagonists and can be used in the treatment of a chemokine-mediated dis...
|
WO/1999/042463A1 |
Quinoxaline compounds are described as well as methods for the preparation and pharmaceutical compositions of same, which are useful as interleukin-8 (IL-8) receptor antagonists and can be used in the treatment of a chemokine-mediated di...
|
WO/1999/041250A1 |
1,4-Dihydropyridine derivatives represented by general formula (I) and antagonists against tolerance to anticancer drugs or anticancer drug potentiators containing as the active ingredient these derivatives, pharmacologically acceptable ...
|
WO/1999/041235A1 |
The present invention relates to a compound of formula (1) wherein A is of formula (2), (3), (4), B is phenyl, pyridyl, pyridazinyl, pyrimidyl, pyrazinyl, thienyl, thiazolyl, furyl or oxazolyl, the ring being substituted on ring carbon a...
|
WO/1999/041244A1 |
The present invention provides novel substituted aminophenyl isoxazoline derivatives of formula (I), wherein R¿1? is H, alkyl, cycloalkyl, alkoxy, amino, or alkylamino; X and Y are the same and different and are H, F, or CH¿3?; W is O,...
|
WO/1999/041253A1 |
Compounds and compositions which are useful for the treatment of viral infections, particularly human Cytomegalovirus infection. The compounds include novel pyrimidine-based derivatives having formula (I) wherein X is a member selected f...
|
WO/1999/040025A1 |
The invention concerns novel ionic compounds with low melting point whereof the onium type cation having at least a heteroatom such as N, O, S or P bearing the positive charge and whereof the anion includes, wholly or partially, at least...
|
WO/1999/040075A1 |
Compounds represented by general formula (I) or salts thereof and prodrugs of the same which have an inhibitory effect on activated blood coagulation factor X and thus are useful as anticoagulating agents. In formula (I), R?1¿ represent...
|
WO/1999/038514A1 |
The present invention is directed to cyclic amines of formula I (wherein R?1¿, R?2¿, R?3¿, m and n are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulat...
|
WO/1999/038844A1 |
The present invention relates to a method for preparing an N-[(aliphatic or aromatic)carbonyl]-2-aminoacetamide compound of formula (I) wherein R¿a? is (II); R¿aa? is hydrogen, optionally substituted aliphatic or optionally substituted...
|
WO/1999/037625A1 |
Compounds are provided having formula (I), wherein R, R¿1?, R¿2?, R¿3? and R¿4? are defined in the specification, which have matrix metalloproteinase inhibiting activity.
|
WO/1999/037637A1 |
A compound of formula (I) wherein A is an optionally substituted heterocyclic group; R is a lower alkoxy; Z is C=O or CH¿2?; and B is a saturated or unsaturated condensed ring group selected from the group consisting of benzazepinyl, be...
|
WO/1999/033460A1 |
Acyl guanidines are provided which are sodium/proton exchange (NHE) inhibitors which have structure (I) wherein n is 1 to 5; X is N or C-R?5¿ wherein R?5¿ is H, halo, alkenyl, alkynyl, alkoxy, alkyl, aryl or heteroaryl; and R?1¿, R?2Â...
|
WO/1999/033781A1 |
Compounds represented by formulae (I, II or III), wherein U is CH, O, or S; Z is -C(R¿2?)(R¿3?), -CH-N(R¿2?)(R¿3?), C(R¿3?)[(CH¿2?)nR¿2?], CH-C(R¿3?)(R¿8?)(CH¿2?)nR¿2?, C[(CH¿2?)nR¿2?]-[CH(R¿3?)(R¿8?)], C[(R¿3?)][CH[(CH¿...
|
WO/1999/032109A1 |
The present invention concerns novel paclitaxel derivatives, their use as antitumor agents, and pharmaceutical formulations.
|
WO/1999/032468A1 |
This invention is provide a compound of formula (I) wherein R?1¿ is an optionally substituted 5- to 6-membered ring; W is a divalent group of formula (a) or (b) wherein the ring A is an optionally substituted 5- to 6-membered aromatic r...
|
WO/1999/032460A1 |
The invention relates to inventive compounds of formula (I), wherein R?1¿, R?2¿, R?3¿ and Ar have the meanings cited in the claims. The inventive compounds are suitable for use in the production of medicaments, e.g. for prophylaxis an...
|
WO/1999/032106A1 |
Methods of treating tumors mediated by raf kinase, with substituted urea compounds, and such compounds per se.
|
WO/1999/032446A1 |
A dihydropyridine derivative represented by formula (I), analogues thereof and medicinally acceptable salts of both exhibit a selective blocking activity against N-type calcium channel, and are therefore useful as therapeutic agents for ...
|
WO/1999/032464A1 |
Compounds of formula (I) and process for protecting and immunizing plants against attack by phytopathogenic microorganisms by applying compounds of formula (I) wherein a) X is CR¿4? and Y is N; or b) X is N and Y is CR¿5?; or c) X and ...
|
WO/1999/031073A1 |
Pyrimidine-5-carboxyamide derivatives represented by general formula (I) or salts thereof, wherein each symbol has the meaning as specified below: X: O, S, NR?1¿, CO, NR?1¿CO, CONR?1¿, C=N-OR?1¿ or a bond; Y: lower alkylene optionall...
|
WO/1999/031077A1 |
A series of arylpiperazine compounds are effective pharmaceuticals for the treatment of conditions related to or affected by the serotonin 1¿A? receptor; the compounds are particularly effective antagonists at that receptor, and are par...
|
WO/1999/031037A1 |
Apoptosis inhibitors containing as the active ingredient compounds represented by general formula (I) or salts thereof, wherein W¿1? represents -O-, -CH¿2?-, etc.; W¿2? represents -CH¿2?-, etc.; W¿3? represents -O-, -CH¿2?-, etc.; ...
|
WO/1999/029671A1 |
Benzoic acid derivatives of general formula (I), wherein the substituents have the meanings cited in the description.
|
WO/1999/029674A1 |
The present invention is concerned with compounds of formula (I) the $i(N)-oxides, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein X represents O, S or NR?3¿; R?1¿ represents hydr...
|
WO/1999/029660A1 |
The invention provides adamantane derivatives represented by formula (I), a process for their preparation, pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions, and their use in therapy. In...
|
WO/1999/029676A1 |
Process for the preparation of a compound of formula (VIII) wherein R¿1? is Cl, F or CF¿3?; R¿2? is H, Cl, F or CF¿3?; and R¿3? is C¿1-4? alkyl; characterized in that a triol of formula II is treated with a ketone or an aldehyde to...
|
WO/1999/029647A1 |
Apoptosis inducers represented by chemical formulae (I), (II), (VIII), (IV), (V), (VI), (III) and (VII); and medicinal compositions containing the same and usable as carcinostatic and the like.
|
WO/1999/029675A1 |
Process for the preparation of a compound of formula (VII) wherein R¿1? is Cl, F or CF¿3?; R¿2? is H, Cl, F or CF¿3?; and R¿3? is C¿1-4? alkyl; characterized in that an olefin of formula (II) is epoxidized to give an oxirane of for...
|
WO/1999/028309A1 |
Compounds of formula (I) wherein m is zero or 1; Q represents a C¿6?-C¿14? aromatic ring system or an optionally substituted, saturated or unsaturated, heteromonocyclic or heterobicyclic ring containing one or two heteroatoms chosen fr...
|
WO/1999/028292A1 |
The invention concerns ionic compositions with high ionic conductivity, comprising a salt with delocalized anionic charge. An ionic composition comprises a salt dissolved in a solvent and has a conductivity higher than 10?-5¿ S.cm?-1¿ ...
|
WO/1999/028282A1 |
A process for preparing a compound of Formula (I); where Q completes an optionally substituted 5- or 6-member saturated carbocyclic ring and R is optionally substituted phenyl or optionally substituted C¿3?-C¿6? cycloalkyl which proces...
|
WO/1999/026927A2 |
The present invention provides compounds, and pharmaceutical compositions containing those compounds, that act as antagonists at metabotropic glutamate receptors. The compounds are useful for treating neurological diseases and disorders....
|
WO/1999/026933A1 |
The present invention relates to novel biheterocyclic derivatives which are factor Xa inhibitors; the pharmaceutically acceptable salts and $i(N)-oxides thereof; their uses as therapeutic agents and the methods of their making.
|
WO/1999/026932A1 |
The present invention relates to novel biheterocyclic derivatives which are factor Xa inhibitors; the pharmaceutically acceptable salts and $i(N)-oxides thereof; their uses as therapeutic agents and the methods of their making.
|
WO/1999/025687A1 |
A treatment process is disclosed that comprises administering an effective amount of an aromatic sulfone hydroxamic acid that exhibits excellent inhibitory activity of one or more matrix metalloprotease (MMP) enzymes, such as MMP-2, MMP-...
|
WO/1999/024425A1 |
Compounds represented by general formula (I) and having both an IL-4 production inhibitory activity and a PDE(IV) inhibitory activity; a medicinal composition comprising an effective amount of any of the compounds and a pharmaceutical ca...
|
WO/1999/024393A1 |
The present invention includes a number of novel intermediates such as the (S)-secondary alcohol of formula (VIIIA) X¿2?-CH¿2?-C*H(OH)-CH¿2?-NH-CO-R¿N? and processes for production of pharmacologically useful oxazolidinones.
|
WO/1999/024420A1 |
A group of novel pyrimidone compounds are inhibitors of the enzyme LDL PLA2 and therefore of use in treating atherosclerosis.
|
WO/1999/023069A1 |
Compounds represented by general formula (1), having NOS inhibitory activities, and being useful as medicines such as a remedy for cerebrovascular disorder, wherein R¿1? represents aminoalkyl, etc.; R¿2? represents hydrogen, lower alky...
|
WO/1999/023079A1 |
The invention relates to compounds of formula (I) or the salts thereof, wherein R?1¿, R?3¿ = H, (substituted) hydrocarbon radical (KW) or (substituted) heterocyclyl, which comprise inclusive substituents 1-30 C-atoms, R?2¿ = R?0¿-Q?0...
|
WO/1999/021838A1 |
The 2-[2-(3,5-dichlorophenyl)ethyl]benzoic acid (V) which is the key intermediate for the preparation of eberconazol (I) through a known sequence of four steps is prepared by catalytic hydrogenation of 2-[2-(3,5-dichlorophenyl)ethenyl]be...
|
WO/1999/021845A2 |
This invention is directed to aminothiazole compounds of formula (I) wherein R?1¿ is a substituted or unsubstituted group selected from: C¿1-6?-alkyl; C¿1-6?-alkenyl; C¿1-6?-alkynyl; C¿1-6?-alkoxyl; C¿1-6?-alcohol; carbocyclic or h...
|
WO/1999/020608A1 |
Compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein one of R?1¿ and R?2¿ is H and the other is N=C(NH¿2?)¿2? or NHC(=NH)NH¿2?, and the other substituents are as defined herein, are urokinase (uPA) inhibit...
|
WO/1999/020269A1 |
Carbapenems substituted with a naphthosultam at position 2 and linked through a CH¿2? group are disclosed. Pharmaceutical compositions and methods of treatment are also included. The naphtosultam is substituted with at least one cationi...
|
WO/1999/020611A1 |
The present invention relates to compound of formula (1), wherein Ar?1¿ represents (A), or (B), or (C); R?12¿ and R?13¿ are independently hydrogen or C¿1-4? alkyl; Ar?2¿ is phenyl or heteroaryl; p is 0 or 1; Ar?3¿ is phenyl, pyridi...
|